SCHEMBL4097715

SCHEMBL4097715

Nc1nc(-c2ccccc2)c2nc(-c3ccc(C=O)o3)ccc2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2E1 P05181 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2B6 P20813 1/20 0.42
CYP2C19 P33261 1/20 0.42
KDM4E B2RXH2 6/20 0.41
ALDH1A1 P00352 4/20 0.41
MAPT P10636 3/20 0.41
RAB9A P51151 2/20 0.41
MEN1 O00255 1/20 0.41
PKM P14618 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ADORA2A P29274 9/20 0.40
NUDT1 P36639 1/20 0.40
POLB P06746 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
LMNA P02545 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4106255 0.81 KDM4E (0.44) KDM4EALDH1A1MAPTMEN1PKM
SCHEMBL4105702 0.81 KDM4E (0.43) CYP2E1CYP3A4CYP2D6CYP2C9CYP2B6
SCHEMBL4107803 0.78 ADORA2A (0.44) ALDH1A1MAPTADORA2ANUDT1MAP4K4
SCHEMBL4112741 0.78 ADORA2A (0.44) CYP3A4CYP2D6CYP2C9KDM4EALDH1A1
SCHEMBL4108111 0.76 ADORA2A (0.56) ADORA2ANUDT1ADORA1ADORA2B
SCHEMBL4103631 0.76 MAP4K4 (0.48) KDM4EALDH1A1MEN1KMT2AADORA2A
SCHEMBL4107999 0.75 ALDH1A1 (0.36) CYP2E1CYP3A4CYP2D6CYP2C9CYP2B6
SCHEMBL4097472 0.75 ADORA2A (0.53) CYP3A4CYP2D6CYP2C9KDM4EALDH1A1
SCHEMBL4112867 0.75 CYP2E1 (0.44) CYP2E1CYP3A4CYP2C9CYP2B6CYP2C19
SCHEMBL4102290 0.73 ADORA2A (0.44) KDM4EALDH1A1MAPTADORA2ANUDT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253696-A1 SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2009-10-08 US claimed
WO-2008009076-A2 SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO claimed
US-8338435-B2 Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections GILEAD SCIENCES, INC. (US) 2012-12-25 US disclosed
US-20090253696-A1 SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2009-10-08 US disclosed
WO-2008009076-A2 SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253696-A1 SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS PNPO, PNP, DPYD CYP2E1 152/4885CYP3A4 57/4885CYP2D6 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.